74 related articles for article (PubMed ID: 34128042)
1. Cost-effectiveness of trifluridine/tipiracil against nivolumab for heavily pretreated metastatic gastric cancer in Japan.
Takushima Y; Igarashi A; Yoshihara H; Shitara K; Doi T
Jpn J Clin Oncol; 2021 Aug; 51(9):1383-1390. PubMed ID: 34128042
[TBL] [Abstract][Full Text] [Related]
2. Cost-Effectiveness of the New Combination Trifluridine/Tipiracil Plus Bevacizumab for the Third-Line Treatment for Metastatic Colorectal Cancer in Italy.
Giuliani J; Mantoan B; Mangiola D; Muraro M; Napoli G; Tommasi M; Fiorica F; Mandarà M
Clin Colorectal Cancer; 2024 Mar; 23(1):1-3. PubMed ID: 37932152
[No Abstract] [Full Text] [Related]
3. Trifluridine/tipiracil versus placebo for third or later lines of treatment in metastatic gastric cancer: an exploratory subgroup analysis from the TAGS study.
Tabernero J; Shitara K; Zaanan A; Doi T; Lorenzen S; Van Cutsem E; Fornaro L; Catenacci DVT; Fougeray R; Moreno SR; Azcue P; Arkenau HT; Alsina M; Ilson DH
ESMO Open; 2021 Aug; 6(4):100200. PubMed ID: 34175675
[TBL] [Abstract][Full Text] [Related]
4. Protocol of a phase II study investigating the efficacy and safety of trifluridine/tipiracil plus ramucirumab as a third-line or later treatment for advanced gastric cancer.
Nakanishi K; Tanaka C; Kanda M; Miyata K; Machida N; Sakai M; Kobayashi D; Teramoto H; Ishiyama A; Sato B; Oshima T; Kajikawa M; Matsushita H; Ishigure K; Yamashita K; Fujitake S; Sueoka S; Asada T; Shimizu D; Sugita S; Kuwatsuka Y; Maeda O; Furune S; Murotani K; Ando Y; Ebata T; Kodera Y
Nagoya J Med Sci; 2024 Feb; 86(1):43-51. PubMed ID: 38505718
[TBL] [Abstract][Full Text] [Related]
5. Comparative cost-effectiveness of nivolumab first-line and second-line therapy for advanced esophageal cancer in Japan.
Kashiwa M
Eur J Health Econ; 2024 Apr; 25(3):459-470. PubMed ID: 37261572
[TBL] [Abstract][Full Text] [Related]
6. Predicting Trifluridine/Tipiracil Treatment Outcomes in Refractory Metastatic Colorectal Cancer Patients: A Multicenter Exploratory Analysis.
Prejac J; Omrčen T; Radić J; Vrdoljak E; Fröbe A; Pleština S
Oncology; 2024; 102(3):217-227. PubMed ID: 37699377
[TBL] [Abstract][Full Text] [Related]
7. Long Term Real-World Outcomes of Trifluridine/Tipiracil in Metastatic Colorectal Cancer-A Single UK Centre Experience.
Tong D; Wang L; Mendis J; Essapen S
Curr Oncol; 2021 Jun; 28(3):2260-2269. PubMed ID: 34207352
[TBL] [Abstract][Full Text] [Related]
8. Sequencing considerations in the third-line treatment of metastatic colorectal cancer.
Barzi A; Bekaii-Saab T
Am J Manag Care; 2024 May; 30(2 Suppl):S31-S35. PubMed ID: 38701364
[TBL] [Abstract][Full Text] [Related]
9. Trifluridine/tipiracil plus ramucirumab in gastric cancer.
Zhu M; Sonbol MB; Yoon HH
Lancet Gastroenterol Hepatol; 2021 Mar; 6(3):154-155. PubMed ID: 33508243
[No Abstract] [Full Text] [Related]
10. Quantitative Analysis of the Concentration of Trifluridine in Tumor Hypoxic Regions Using a Novel Platform Combining Functional Endoscopy and Mass Spectrometry.
Koganemaru S; Fuchigami H; Yamashita H; Morizono C; Sunakawa H; Kawazoe A; Nakamura Y; Kuboki Y; Shitara K; Yano T; Doi T; Yasunaga M
Clin Pharmacol Ther; 2024 Jan; 115(1):62-70. PubMed ID: 37803526
[TBL] [Abstract][Full Text] [Related]
11. Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y; Ito N; Mimura Y; Sugiyama Y; Ogawa R; Shimura T; Nakamura M; Kawakita D; Hamamoto S; Uemura T; Yokota K; Iida M; Odagiri K; Kimura Y; Hotta Y; Komatsu H; Okuda K; Niimi A; Yasui T; Iwasaki S; Morita A; Kataoka H; Takiguchi S; Furukawa-Hibi Y
Asia Pac J Clin Oncol; 2024 Apr; ():. PubMed ID: 38682421
[TBL] [Abstract][Full Text] [Related]
12. Nivolumab in Heavily Pretreated Metastatic Gastric Cancer Patients: Real-Life Data from a Western Population.
Petrillo A; Tirino G; Zito Marino F; Pompella L; Sabetta R; Panarese I; Pappalardo A; Caterino M; Ventriglia A; Laterza MM; Morgillo F; Orditura M; Ciardiello F; Franco R; De Vita F
Onco Targets Ther; 2020; 13():867-876. PubMed ID: 32099391
[TBL] [Abstract][Full Text] [Related]
13. The cost of schizophrenia in Japan.
Sado M; Inagaki A; Koreki A; Knapp M; Kissane LA; Mimura M; Yoshimura K
Neuropsychiatr Dis Treat; 2013; 9():787-98. PubMed ID: 23785238
[TBL] [Abstract][Full Text] [Related]
14. Cost of shifting from healthcare to long-term care in later life across major diseases: analysis of end-of-life care during the last 24 months of life.
Terada T; Nakamura K; Seino K; Kizuki M; Inase N
J Rural Med; 2018 May; 13(1):40-47. PubMed ID: 29875896
[No Abstract] [Full Text] [Related]
15. Drug Monographs: Trabectedin and Trifluridine-Tipiracil.
Solimando DA; Waddell JA
Hosp Pharm; 2016 Feb; 51(2):120-128. PubMed ID: 38746764
[TBL] [Abstract][Full Text] [Related]
16. Trifluridine/Tipiracil: Old Drug, New Tricks.
Jeffers KD
J Adv Pract Oncol; 2016; 7(4):449-453. PubMed ID: 29226002
[No Abstract] [Full Text] [Related]
17. A Phase I Study of APX005M and Cabiralizumab with or without Nivolumab in Patients with Melanoma, Kidney Cancer, or Non-Small Cell Lung Cancer Resistant to Anti-PD-1/PD-L1.
Weiss SA; Djureinovic D; Jessel S; Krykbaeva I; Zhang L; Jilaveanu L; Ralabate A; Johnson B; Levit NS; Anderson G; Zelterman D; Wei W; Mahajan A; Trifan O; Bosenberg M; Kaech SM; Perry CJ; Damsky W; Gettinger S; Sznol M; Hurwitz M; Kluger HM
Clin Cancer Res; 2021 Sep; 27(17):4757-4767. PubMed ID: 34140403
[TBL] [Abstract][Full Text] [Related]
18. Comparison of gemcitabine-based chemotherapies for advanced biliary tract cancers by renal function: an exploratory analysis of JCOG1113.
Ueno M; Morizane C; Okusaka T; Mizusawa J; Kataoka T; Ikeda M; Ozaka M; Okano N; Sugimori K; Todaka A; Shimizu S; Mizuno N; Yamamoto T; Sano K; Tobimatsu K; Katanuma A; Miyamoto A; Yamaguchi H; Nishina T; Shirakawa H; Kojima Y; Oono T; Kawamoto Y; Furukawa M; Iwai T; Sudo K; Miyakawa H; Yamashita T; Yasuda I; Takahashi H; Kato N; Shioji K; Shimizu K; Nakagohri T; Kamata K; Ishii H; Furuse J;
Sci Rep; 2021 Jun; 11(1):12885. PubMed ID: 34145336
[TBL] [Abstract][Full Text] [Related]
19. Avelumab alone or in combination with chemotherapy versus chemotherapy alone in platinum-resistant or platinum-refractory ovarian cancer (JAVELIN Ovarian 200): an open-label, three-arm, randomised, phase 3 study.
Pujade-Lauraine E; Fujiwara K; Ledermann JA; Oza AM; Kristeleit R; Ray-Coquard IL; Richardson GE; Sessa C; Yonemori K; Banerjee S; Leary A; Tinker AV; Jung KH; Madry R; Park SY; Anderson CK; Zohren F; Stewart RA; Wei C; Dychter SS; Monk BJ
Lancet Oncol; 2021 Jul; 22(7):1034-1046. PubMed ID: 34143970
[TBL] [Abstract][Full Text] [Related]
20. Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer.
Sugawara S; Lee JS; Kang JH; Kim HR; Inui N; Hida T; Lee KH; Yoshida T; Tanaka H; Yang CT; Nishio M; Ohe Y; Tamura T; Yamamoto N; Yu CJ; Akamatsu H; Namba Y; Sumiyoshi N; Nakagawa K
Ann Oncol; 2021 Sep; 32(9):1137-1147. PubMed ID: 34139272
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
